JP2018527333A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527333A5
JP2018527333A5 JP2018504932A JP2018504932A JP2018527333A5 JP 2018527333 A5 JP2018527333 A5 JP 2018527333A5 JP 2018504932 A JP2018504932 A JP 2018504932A JP 2018504932 A JP2018504932 A JP 2018504932A JP 2018527333 A5 JP2018527333 A5 JP 2018527333A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
mospd2
composition according
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018504932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527333A (ja
JP6949818B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/054584 external-priority patent/WO2017021857A1/en
Publication of JP2018527333A publication Critical patent/JP2018527333A/ja
Publication of JP2018527333A5 publication Critical patent/JP2018527333A5/ja
Application granted granted Critical
Publication of JP6949818B2 publication Critical patent/JP6949818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018504932A 2015-07-31 2016-07-29 運動精子ドメイン含有タンパク質2及びがん Active JP6949818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199571P 2015-07-31 2015-07-31
US62/199,571 2015-07-31
PCT/IB2016/054584 WO2017021857A1 (en) 2015-07-31 2016-07-29 Motile sperm domain containing protein 2 and cancer

Publications (3)

Publication Number Publication Date
JP2018527333A JP2018527333A (ja) 2018-09-20
JP2018527333A5 true JP2018527333A5 (cg-RX-API-DMAC7.html) 2020-04-23
JP6949818B2 JP6949818B2 (ja) 2021-10-13

Family

ID=57942495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504932A Active JP6949818B2 (ja) 2015-07-31 2016-07-29 運動精子ドメイン含有タンパク質2及びがん

Country Status (10)

Country Link
US (2) US20190040150A1 (cg-RX-API-DMAC7.html)
EP (2) EP3735977A1 (cg-RX-API-DMAC7.html)
JP (1) JP6949818B2 (cg-RX-API-DMAC7.html)
CN (1) CN108135933B (cg-RX-API-DMAC7.html)
AU (1) AU2016303474B2 (cg-RX-API-DMAC7.html)
CA (1) CA2991868C (cg-RX-API-DMAC7.html)
ES (1) ES2839456T3 (cg-RX-API-DMAC7.html)
IL (1) IL257260B (cg-RX-API-DMAC7.html)
NZ (1) NZ738875A (cg-RX-API-DMAC7.html)
WO (1) WO2017021857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735977A1 (en) 2015-07-31 2020-11-11 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
ES2963268T3 (es) 2015-07-31 2024-03-26 Immunewalk Therapeutics Inc Proteína 2 que contiene el dominio de esperma móvil e inflamación
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN112041336A (zh) * 2018-03-13 2020-12-04 脉管生物生长有限公司 针对mospd2和t细胞或nk细胞特异性分子的双特异性抗体
EP3597193A1 (en) 2018-07-16 2020-01-22 Universitat Autònoma de Barcelona Therapeutic use of afatinib in cancer
CN116710130A (zh) * 2020-09-10 2023-09-05 脉管生物生长有限公司 含活动精子结构域的蛋白质2抗体及其使用方法
IL301202A (en) 2020-09-10 2023-05-01 Vascular Biogenics Ltd Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them
US20250277052A1 (en) * 2021-03-29 2025-09-04 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2, integrin beta2 and cd63
USD1105906S1 (en) * 2023-11-29 2025-12-16 Ufp Industries, Inc. Removable clip
USD1106811S1 (en) * 2023-11-29 2025-12-23 Ufp Industries, Inc. Removable clip

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
JP2004537969A (ja) * 2000-12-08 2004-12-24 インサイト・ゲノミックス・インコーポレイテッド 脂質関連分子
WO2002063005A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Lipid-associated molecules
AU2002309917A1 (en) * 2001-05-18 2002-12-03 Incyte Genomics, Inc. Lipid-associated molecules
US20040171009A1 (en) * 2001-05-18 2004-09-02 Tang Y. Tom Lipid-associated molecules
WO2003025150A2 (en) * 2001-09-21 2003-03-27 Incyte Genomics, Inc. Lipid-associated molecules
DK1463487T3 (da) * 2001-12-19 2010-08-23 Res Dev Foundation Liposomal afgivelse af vitamin-E baserede forbindelser
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
JP4810642B2 (ja) * 2004-11-30 2011-11-09 秋田県 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
US20070218116A1 (en) 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
KR20110095288A (ko) * 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
US20120020954A1 (en) 2009-03-30 2012-01-26 Anat Achiron Methods of predicting clinical course and treating multiple sclerosis
DK2443449T3 (en) 2009-06-15 2017-05-15 Cardiodx Inc DETERMINATION OF RISK OF CORONARY ARTERY DISEASE
WO2011159951A2 (en) 2010-06-17 2011-12-22 Sanford-Burnham Medical Research Institute Targeting tumor associated macrophages using bisphosphonate-loaded particles
EP2420228A1 (en) * 2010-08-05 2012-02-22 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
WO2012121679A1 (en) * 2011-03-09 2012-09-13 Agency For Science, Technology And Research Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage
EP2791101B1 (en) * 2011-12-12 2019-09-18 Vascular Biogenics Ltd. Treatment of non-alcoholic steatohepatitis
CN103592432B (zh) * 2013-10-15 2015-06-03 重庆市公安局 一种免疫磁珠分离精子与上皮细胞混合斑中精子的方法
ES2963268T3 (es) 2015-07-31 2024-03-26 Immunewalk Therapeutics Inc Proteína 2 que contiene el dominio de esperma móvil e inflamación
EP3735977A1 (en) 2015-07-31 2020-11-11 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
IL301202A (en) 2020-09-10 2023-05-01 Vascular Biogenics Ltd Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them
US20250277052A1 (en) 2021-03-29 2025-09-04 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2, integrin beta2 and cd63

Similar Documents

Publication Publication Date Title
AU2020201289B2 (en) Carrier-antibody compositions and methods of making and using the same
US20220211870A1 (en) Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11945875B2 (en) Motile sperm domain containing protein 2 and cancer
EP2903610B1 (en) Cancer treatments
JP2019526579A (ja) T細胞癌を標的とする為の方法及び組成物
JP7761490B2 (ja) 小細胞肺がんの併用療法用キノリン誘導体
JP2024513505A (ja) 腫瘍を治療するための組成物及び方法
KR20220133996A (ko) 암 및 암 전이를 치료하기 위한 병용 요법
CA3233721A1 (en) Methods of treating cancer and the pharmaceutical compositions thereof
JP7579284B2 (ja) セマフォリン4d遮断(sema4d)とdc1療法との併用療法
CN108883068B (zh) 乳癌治疗
JP2021517153A (ja) Mospd2およびt細胞またはnk細胞特異的分子に対する二重特異性抗体 電子出願された配列表の参照
JP2021517153A5 (ja) Mospd2およびt細胞またはnk細胞特異的分子に対する二重特異性抗体
WO2016191703A2 (en) Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer
JP2026514110A (ja) がんの処置および予防のための組合せ
RU2801828C2 (ru) Комбинированная терапия блокированием семафорина 4d (sema4d) и терапией дк1
HK40041339A (en) Motile sperm domain containing protein 2 and cancer
Zhou Development and Evaluation of LSR-and CD276-Targeted Therapies for Triple-Negative Breast Cancer
WO2024159105A1 (en) Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody
Bien et al. Liposomal irinotecan in the treatment of refractory pancreatic cancer
OA18218A (en) Carrier-antibody compositions and methods of making and using the same
HK1254515B (en) Motile sperm domain containing protein 2 and cancer
HK1189492A (en) Dosing for treatment with anti-egfl7 antibodies